|
1
|
Fletcher CDM, Sundaram M, Rydholm A,
Coindre JM and Singer S: Soft tissue tumours: Epidemiology,
clinical features, histopathological typing and grading. World
Health Organization, International Agency for Research on Cancer.
Pathology and Genetics of Tumours of Soft Tissue and Bone. Fletcher
CDM, Unni KK and Mertens F: IARC Press; Lyon: pp. 12–18. 2002
|
|
2
|
Jones NB, Iwenofu H, Scharschmidt T and
Kraybill W: Prognostic factors and staging for soft tissue
sarcomas: an update. Surg Oncol Clin N Am. 21:187–200. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Taylor BS, Barretina J, Maki RG, Antonescu
CR, Singer S and Ladanyi M: Advances in sarcoma genomics and new
therapeutic targets. Nat Rev Cancer. 11:541–557. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ottaiano A, De Chiara A, Fazioli F,
Talamanca AA, Mori S, Botti G, Milano A and Apice G: Biological
prognostic factors in adult soft tissue sarcomas. Anticancer Res.
25:4519–4526. 2005.PubMed/NCBI
|
|
5
|
Endl E and Gerdes J: The Ki-67 protein:
fascinating forms and an unknown function. Exp Cell Res.
257:231–237. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Brown DC and Gatter KC: Ki67 protein: the
immaculate deception? Histopathology. 40:2–11. 2002. View Article : Google Scholar
|
|
7
|
Hoos A, Stojadinovic A, Mastorides S,
Urist MJ, Polsky D, Di Como CJ, Brennan MF and Cordon-Cardo C: High
Ki-67 proliferative index predicts disease specific survival in
patients with high-risk soft tissue sarcomas. Cancer. 92:869–874.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Heslin MJ, Cordon-Cardo C, Lewis JJ,
Woodruff JM and Brennan MF: Ki-67 detected by MIB-1 predicts
distant metastasis and tumor mortality in primary, high grade
extremity soft tissue sarcoma. Cancer. 83:490–497. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hall KT, Boumsell L, Schultze JL,
Boussiotis VA, Dorfman DM, Cardoso AA, Bensussan A, Nadler LM and
Freeman GJ: Human CD100, a novel leukocyte semaphorin that promotes
B-cell aggregation and differentiation. Proc Natl Acad Sci USA.
93:11780–11785. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Goodman CS, Kolodkin AL, Luo Y, Püschel AW
and Raper JA: Unified nomenclature for the semaphorins/collapsins.
Cell. 97:551–552. 1999. View Article : Google Scholar
|
|
11
|
Kumanogoh A, Watanabe C, Lee I, Wang X,
Shi W, Araki H, Hirata H, Iwahori K, Uchida J, Yasui T, Matsumoto
M, Yoshida K, Yakura H, Pan C, Parnes JR and Kikutani H:
Identification of CD72 as a lymphocyte receptor for the class IV
semaphoring CD100: a novel mechanism for regulating B cell
signaling. Immunity. 13:621–631. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tessier-Lavigne M and Goodman SC: The
molecular biology of axon guidance. Science. 274:1123–1133. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Luo Y, Raible D and Raper JA: Collapsin: a
protein in brain that induces the collapse and paralysis of
neuronal growth cones. Cell. 75:217–227. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kolodkin AL, Matthes DJ and Goodman CS:
The semaphorin genes encode a family of transmembrane and secreted
growth cone guidance molecules. Cell. 75:1389–1399. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Behar O, Golden JA, Mashimo H, Schoen FJ
and Fishman MC: Semaphorin III is needed for normal patterning and
growth of nerves, bones and heart. Nature. 383:525–528. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kitsukawa T, Shimono A, Kawakami A, Kondoh
H and Fujisawa H: Overexpression of a membrane protein, neuropilin,
in chimeric mice causes anomalies in the cardiovascular system,
nervous system and limbs. Development. 121:4309–4318. 1995.
|
|
17
|
Roche J, Boldog F, Robinson M, Robinson L,
Varella-Garcia M, Swanton M, Waggoner B, Fishel R, Franklin W,
Gemmill R and Drabkin H: Distinct 3p21.3 deletions in lung cancer
and identification of a new human semaphorin. Oncogene.
12:1289–1297. 1996.PubMed/NCBI
|
|
18
|
Sekido Y, Bader S, Latif F, Chen JY, Duh
FM, Wei MH, et al: Human semaphorins A(V) and IV reside in the
3p21.3 small cell lung cancer deletion region and demonstrate
distinct expression patterns. Proc Natl Acad Sci USA. 93:4120–4125.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mizui M, Kumanogoh A and Kikutani H:
Immune semaphorins: novel features of neural guidance molecules. J
Clin Immunol. 29:1–11. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Conrotto P, Valdembri D, Corso S, Serini
G, Tamagnone L, Comoglio PM, Bussolino F and Giordano S: Sema4D
induces angiogenesis through Met recruitment by Plexin B1. Blood.
105:4321–4329. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Conrotto P, Corso S, Gamberini S, Comoglio
PM and Giordano S: Interplay between scatter factor receptors and B
plexins controls invasive growth. Oncogene. 23:5131–5137. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ch’ng E, Tomita Y, Zhang B, He J, Hoshida
Y, Qiu Y, Morii E, Nakamichi I, Hamada K, Ueda T and Aozasa K:
Prognostic significance of CD100 expression in soft tissue sarcoma.
Cancer. 110:164–172. 2007.PubMed/NCBI
|
|
23
|
Ch’ng ES and Kumanogoh A: Roles of Sema4D
and Plexin-B1 in tumor progression. Mol Cancer.
9:2512010.PubMed/NCBI
|
|
24
|
Kato S, Kubota K, Shimamura T, Shinohara
Y, Kobayashi N, Watanabe S, Yoneda M, Inamori M, Nakamura F,
Ishiguro H, Nakaigawa N, Nagashima Y, Taguri M, Kubota Y, Goshima
Y, Morita S, Endo I, Maeda S, Nakajima A and Nakagama H: Semaphorin
4D, a lymphocyte semaphorin, enhances tumor cell motility through
binding its receptor, plexinB1, in pancreatic cancer. Cancer Sci.
102:2029–2037. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rody A, Holtrich U, Gaetje R, Gehrmann M,
Engels K, von Minckwitz G, Loibl S, Diallo-Danebrock R, Ruckhäberle
E, Metzler D, Ahr A, Solbach C, Karn T and Kaufmann M: Poor outcome
in estrogen receptor-positive breast cancers predicted by loss of
plexin B1. Clin Cancer Res. 13:1115–1122. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gerdes J: Ki-67 and other proliferation
markers useful for immunohistological diagnostic and prognostic
evaluations in human malignancies. Semin Cancer Biol. 1:199–206.
1990.PubMed/NCBI
|
|
27
|
Choong PF, Akerman M, Willén H, Andersson
C, Gustafson P, Baldetorp B, Fernö M, Alvegård T and Rydholm A:
Prognostic value of Ki-67 expression in 182 soft tissue sarcomas.
Proliferation - a marker of metastasis? APMIS. 102:915–924. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ueda T, Aozasa K, Tsujimoto M, Ohsawa M,
Uchida A, Aoki Y, Ono K and Matsumoto K: Prognostic significance of
Ki-67 reactivity in soft tissue sarcomas. Cancer. 63:1607–1611.
1989. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jensen V, Sørensen FB, Bentzen SM,
Ladekarl M, Nielsen OS, Keller J and Jensen OM: Proliferative
activity (MIB-1 index) is an independent prognostic parameter in
patients with high-grade soft tissue sarcomas of subtypes other
than malignant fibrous histiocytomas: a retrospective
immunohistological study including 216 soft tissue sarcomas.
Histopathology. 32:536–546. 1998. View Article : Google Scholar
|
|
30
|
Huutanen RL, Blomqvist CP, Wiklund TA,
Böhling TO, Virolainen MJ, Tukiainen EJ, Tribukait B and Andresson
LC: Comparison of the Ki-67 score and S-phase fraction as
prognostic variables in soft-tissue sarcoma. Br J Cancer.
79:945–951. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Popiolek D, Yee H, Levine P, Vamvakas E
and Demopoulos RI: MIB1 as a possible predictor of recurrence in
low-grade endometrial stromal sarcoma of the uterus. Gynecol Oncol.
90:353–357. 2003. View Article : Google Scholar : PubMed/NCBI
|
